Beneficial effects of CCR1 blockade on the progression of chronic renal allograft damage

American Journal of Transplantation

Volumn 7, Issue 3, 2007, Pages 527-537

  Bedke, J ^a,b   Kiss, E ^a   Schaefer, L ^c   Behnes, C L ^a   Bonrouhi, M ^a   Gretz, N ^b   Horuk, R ^d   Diedrichs Moehring, M ^e   Wildner, G ^e   Nelson, P J ^e   Grone H J ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d BAYER AG   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

Biglycan; BX 471; CCR1; Chemokines; Chronic allograft nephropathy

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; BIGLYCAN; CD8 ANTIGEN; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; HEME OXYGENASE 1; KI 67 ANTIGEN; OSTEOPONTIN; TRANSFORMING GROWTH FACTOR BETA1;

ACUTE GRAFT REJECTION; ACUTE PHASE RESPONSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; CELL PROLIFERATION; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FIBROSING ALVEOLITIS; FISCHER 344 RAT; GENE EXPRESSION REGULATION; GLOMERULOSCLEROSIS; IN SITU HYBRIDIZATION; IN VITRO STUDY; INTERSTITIUM; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; LEWIS RAT; MALE; MONONUCLEAR CELL; MYOFIBROBLAST; NONHUMAN; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; STATISTICAL SIGNIFICANCE;

ANIMALS; DISEASE PROGRESSION; EXTRACELLULAR MATRIX PROTEINS; FIBROSIS; GRAFT REJECTION; GRAFT SURVIVAL; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MACROPHAGES; MODELS, ANIMAL; PHENYLUREA COMPOUNDS; PIPERIDINES; PROTEOGLYCANS; RATS; RECEPTORS, CHEMOKINE; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 33847701747     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01654.x     Document Type: Article

References (51)

1. Becker GJ, Hewitson TD. The role of tubulointerstitial injury in chronic renal failure. Curr Opin Nephrol Hypertens 2000; 9: 133-138.
2. Tang WW, Van GY, Qi M. Myofibroblast and alpha 1 (III) collagen expression in experimental tubulointerstitial nephritis. Kidney Int 1997; 51: 926-931.
3. Haskell CA, Ribeiro S, Horuk R. Chemokines in transplant rejection. Curr Opin Investig Drugs 2002; 3: 399-405.
4. Anders HJ, Ninichuk V, Schlondorff D. Progression of kidney disease: Blocking leukocyte recruitment with chemokine receptor CCR1 antagonists. Kidney Int 2006; 69: 29-32.
5. Pattison J, Nelson PJ, Huie P et al. RANTES chemokine expression in cell-mediated transplant rejection of the kidney. Lancet 1994; 343: 209-211.
6. Grone HJ, Weber C, Weber KS et al. Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: Blocking monocyte arrest and recruitment. FASEB J 1999; 13: 1371-1383.
7. Yun JJ, Whiting D, Fischbein MP et al. Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection. Circulation 2004; 109: 932-937.
8. Bedke J, Stojanovic T, Grone HJ et al. Met-RANTES improves acute-rejection-induced microvascular injury in rat small bowel transplantation. Transplant Proc 2002; 34: 1049.
9. Weber C, Weber KSC, Klier C et al. Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and TH1-like/CD45RO1 T cells. Blood 2001; 97: 1444-1446.
10. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998; 19: 568-574.
11. Eis V, Luckow B, Vielhauer V et al. Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction. J Am Soc Nephrol 2004; 15: 337-347.
12. Liang M, Mallari C, Rosser M et al. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem 2000; 275: 19000-19008.
13. Horuk R, Clayberger C, Krensky AM et al. A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J Biol Chem 2001; 276: 4199-4220.
14. Horuk R, Shurey S, Ng HP et al. CCR1-specific non-peptide antagonist: Efficacy in a rabbit allograft rejection model. Immunol Lett 2001; 76: 193-201.
15. Young MF, Bi Y, Ameye L, Chen XD. Biglycan knockout mice: New models for musculoskeletal diseases. Glycoconj J 2003; 19: 257-262.
16. Kresse H, Scḧonherr E. Proteoglycans of the extracellular matrix and growth control. J Cell Physiol 2001; 189: 266-274.
17. Riessen R, Isner JM, Blessing E, Loushin C, Nikol S, Wight TN. Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. Am J Pathol 1994; 144: 962-974.
18. Stokes MB, Holler S, Cui Y et al. Expression of decorin, biglycan, and collagen type I in human renal fibrosing disease. Kidney Int 2000; 57: 487-498.
19. Schaefer L, Babelova A, Kiss E et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005; 115: 2223-2233.
20. Vielhauer V, Anders HJ, Mack M et al. Obstructive nephropathy in the mouse: Progressive fibrosis correlates with tubulointerstitial chemokine expression and accumulation of CC chemokine receptor 2- and 5-positive leukocytes. J Am Soc Nephrol 2001; 12: 1173-1187.
21. Schaefer L, Macakova K, Raslik I et al. Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol 2002; 160: 1181-1191.
22. Anders HJ, Vielhauer V, Frink M et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest 2002; 109: 251-259.
23. Lee S. An improved technique of renal transplantation in the rat. Surgery 1967; 61: 771-773.
24. Grone HJ and Helmchen U. Impairment and recovery of the clipped kidney in two kidneys, one clip hypertensive rats during and after antihypertensive therapy. Lab Invest 1986; 54: 645-655.
25. Kiss E, Adams J, Grone HJ,Wagner J. Isotretinoin ameliorates renal damage in experimental acute renal allograft rejection. Transplantation 2003; 76: 480-489.
26. Adams J, Kiss E, Arroyo ABV et al. 13-cis retinoic acid inhibits development and induces regression of chronic allograft nephropathy. Am J Pathol 2005; 167: 285-298.
27. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
28. Schaefer L, Hausser H, Altenburger M et al. Decorin, biglycan and their endocytosis receptor in rat renal cortex. Kidney Int 1998; 54: 1529-1541.
29. Schaefer L, Raslik I, Grone HJ et al. Small proteoglycans in human diabetic nephropathy: Discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin. FASEB J 2001; 15: 559-561.
30. Fisher LW, Termine JD, Young MF. Deduced protein sequence of bone small proteoglycan I (biglycan) shows homology with proteoglycan II (decorin) and several nonconnective tissue proteins in a variety of species. J Biol Chem 1989; 15: 4571-4576.
31. Wildner G, Thurau SR. Cross-reactivity between an HLA-B27-derived peptide and a retinal autoantigen peptide: A clue to major histocompatibility complex association with autoimmune disease. Eur J Immunol 1994; 24: 2579-2585.
32. Avihingsanon Y, Ma N, Csizmadia E et al. Expression of protective genes in human renal allografts: A regulatory response to injury associated with graft rejection. Transplantation 2002; 73: 1079-1085.
33. Gao W, Topham PS, King JA et al. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest 2000; 105: 35-44.
34. Adams DH, Russell ME, Hancock WW, Sayegh MH, Wyner LR, Karnovsky MJ. Chronic rejection in experimental cardiac transplantation: Studies in the Lewis-F344 model. Immunol Rev 1993; 134: 5-19.
35. Grau V, Herbst B, Steiniger B. A preserved native kidney alters acute renal allograft rejection in the rat. Scand J Immunol 1997; 46: 254-261.
36. Sanfilippo F, Vaughn WK, Spees EK. The association of pretransplant native nephrectomy with decreased renal allograft rejection. Transplantation 1984; 37: 256-260.
37. Gunther E, Walter L. The major histocompatibility complex of the rat (Rattus norvegicus). Immunogenetics 2001; 53: 520-542.
38. Paul LC. Chronic allograft nephropathy: An update. Kidney Int 1999 56: 783-793.
39. Nadeau KC, Azuma H, Tilney NL. Sequential cytokine dynamics in chronic rejection of rat renal allografts: roles for cytokines RANTES and MCP-1. Proc Natl Acad Sci USA 1995; 92: 8729-8733.
40. Ninichuk V, Gross O, Reichel C et al. Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease. J Am Soc Nephrol 2005; 16: 977-985.
41. Chandraker A, Azuma H, Nadeau K et al. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest 1998; 101: 2309-2318.
42. Futamatsu H, Suzuki J, Koga N et al. A CCR1 antagonist prevents the development of experimental autoimmune myocarditis in association with T cell inactivation. J Mol Cell Cardiol 2006; 40: 853-861.
43. Liebert M, Kunz HW, Gill TJ 3rd, Cramer DV. CML characterization of a product of a second class I locus in the rat MHC. Immunogenetics 1982; 16: 143-155.
44. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996; 7: 2495-2508.
45. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001; 107: 1055-1061.
46. Alchi B, Nishi S, Kondo D et al. Osteopontin expression in acute renal allograft rejection. Kidney Int 2005; 67: 886-896.
47. Ashkar S, Weber GF, Panoutsakopoulou V et al. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science 2000; 287: 860-864.
48. Soares MP, Lin Y, Anrather J et al. Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med 1998; 4: 1073-1077.
49. Baan C, Peeters A, Lemos F et al. Fundamental role for HO-1 in the self-protection of renal allografts. Am J Transplant 2004; 4: 811-818.
50. Lin H, Wilson JE, Roberts CR et al. Biglycan, decorin, and versican protein expression patterns in coronary arteriopathy of human cardiac allograft: Distinctness as compared to native atherosclerosis. J Heart Lung Transplant 1996; 15: 1233-1247.
51. Pattison J, Nelson PJ, Huie P et al. RANTES chemokine expression in cell-mediated transplant rejection of the kidney. Lancet 1994; 22: 209-211.